How to: Establish and run a stool bank

Terveer, Elisabeth M.; Beurden, Yvette H. van; Goorhuis, Abraham; Seegers, Jos F. M. L.; Bauer, Martijn P.; Nood, Els van; Dijkgraaf, Marcel G. W.; Mulder, Chris J.; Vandenbroucke-Grauls, Christina M. J. E.; Verspaget, Hein W.; Keller, Josbert J.; Kuijper, Ed J.

doi:10.1016/j.cmi.2017.05.015

Cited by 129 publications

(151 citation statements)

References 65 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…As discussed above, there is an absence of published studies to support the recommendations in this section (although the experience of setting up a nationwide stool bank has recently been reported from The Netherlands129). This section is therefore based on the working group’s expert opinion and experience of developing FMT services.…”

Section: Basic Requirements For Implementing a Fmt Servicementioning

confidence: 98%

“…The working group discussed a recent retrospective study demonstrating that exposure to non-anti-CDI antimicrobials within 8 weeks of FMT is associated with an approximate threefold risk of FMT failure (n=8/29 failures with antibiotic exposure vs 36/320 failures without antibiotic exposure) 128. Similarly, the experience of the large pan-Netherlands stool bank129 was that ~50% of their failures of FMT in the treatment of recurrent CDI occurred in patients who had received antibiotics within 1 month of their FMT. For patients requiring long term antibiotics, the working group’s expert opinion was that such patients should still be eligible for FMT, but that the regimen for the use of non-anti-CDI antibiotics should be decided on a case by case basis, based on factors including response to FMT and/or strength of indication of antibiotics.…”

Section: Rationale For Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish

Quraishi

Segal

et al. 2018

Gut

261

187

View full text Add to dashboard Cite

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

show abstract

Section: Basic Requirements For Implementing a Fmt Servicementioning

confidence: 98%

Section: Rationale For Recommendationsmentioning

confidence: 99%

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish

Quraishi

Segal

et al. 2018

Gut

261

187

View full text Add to dashboard Cite

show abstract

“…Given the potential implications of transferring pathogenic microorganisms, a cautious approach to screening has been applied in most studies and guidelines . This is analogous with the procedures employed by blood service organizations and emphasizes the need for voluntary (i.e., unpaid) donations.…”

Section: Infrastructure Of An Fmt Servicementioning

confidence: 99%

Banking feces: a new frontier for public blood banks?

et al. 2019

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection and is potentially beneficial in other microbiota-related disorders. The provision of FMT in routine clinical practice requires an extensive infrastructure that is reliant on voluntary donors. Alongside an increasing demand for FMT, the logistic barriers of a large-scale donor-dependent operation and the difficulties among health authorities to regulate FMT limit the dissemination of sustainable FMT services. Blood centers are large organizations that handle a multitude of donordependent operations on a daily basis. Blood and feces share many of the same dependencies, and feces may present a new opportunity for the blood services to handle. In this paper, we describe how an FMT service may be established and embedded within the blood service infrastructure, and we explain the benefits of using blood donors as feces donors. We further explore the current indications of FMT, the challenges related to the lack of legislation, and the future perspectives for blood banks to meet a new and increasing demand. ABBREVIATIONS: CD = Clostridioides difficile; EUTCD = European Tissue and Cells Directive; FMT = fecal microbiota transplantation; IND = investigational new drug; rCDI = recurrent Clostridioides difficile infection. From the

show abstract

“…Stool banks should only provide access to screened stool that can be traced to the donor and for documenting adverse events in the short, medium and long term. [12] This division provides a practical organisational structure and clarifies both the tasks and the necessary personnel to maintain an operational stool bank nationally or regionally.…”

Section: Editorialmentioning

confidence: 99%